The global gene therapy market is projected to experience substantial growth, with an estimated revenue of USD 11.07 billion by 2025 and expected to reach approximately USD 63.52 billion by 2035, driven by advancements in biotechnology and a growing emphasis on personalized medicine, expanding at a CAGR of 19.09% from 2026 to 2035.
North America currently holds a dominant market share, contributing around 54% in 2025, while the Asia Pacific region is anticipated to grow the fastest. The gene silencing segment led the market in 2025, with viral vectors being the most commonly used delivery mechanism. The oncology therapeutic area is also a major contributor, as gene therapies are transforming treatment strategies for various cancers.
Key growth factors include rising incidence of chronic diseases, increased R&D investments, and favorable regulatory environments. However, challenges like high development costs and complex manufacturing processes for gene therapies may hinder progress. The market is further influenced by innovations in non-viral delivery systems, epigenetic modification techniques, and the growth of point-of-care manufacturing.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.precedenceresearch.com/gene-therapy-market
